Social media can be used for achieving professional growth, establishing oneself as a thought leader, collaborating with KOLs, to gain and spread medical education, and more. Our blog sums up all these emerging ways MSLs and medical affairs can leverage the power of social media.
On March 12, 2021, LARVOL teamed up with Medical Affairs Professional Society (MAPS) to record a podcast on “Social Media in Medical Affairs: Beyond Passive Listening” as a part of the "Elevate" podcast series. The podcast covered questions related to social listening, compliance, and stakeholder engagement as well as the evolving role of new digital tools and platforms in medical affairs success. The conversation was moderated by Garth Sundem, Communications Director at MAPS, and included Luca Dezzani, Franchise Head Immuno-Oncology, AstraZeneca, and Bruno Larvol, CEO and Founder of LARVOL.
The discussion highlighted several points such as most medical affairs professionals being comfortable with social listening although it is still in exceedingly early stages. Bruno mentioned that the pandemic has accelerated the speed of technology use and many customers are having to explore how to do more than listening, “Right now they are learning how to listen actively, and especially, to use social media to identify opportunities for engagement, for example, at webinars, at symposiums…they are looking at how to engage in a way that would be compliant.”
Another thought that emerged was that currently, the number of KOLs that are active in social media is still a small subset of all KOLs. These KOLs who are active on social channels are being called Digital Opinion Leaders (DOLs).
We’ve summarized the key messages from this podcast and enlisted three other emerging uses of social media beyond passive social listening that can be useful for medical affairs and MSLs.
#1 Professional growth & being a thought leader/Attracting talent
There are two angles to this – organizational perspective and individual perspective.
Organizational perspective - Social media offers an amazing opportunity for pharmaceutical companies to establish thought leadership, in medical affairs specifically. Being thought leaders in medical affairs, in particular, is a good way of attracting the right talent and the brightest of minds.
Individual perspective/personal use – The flip side or the plus side to the above point is that if you’re an MSL looking for career opportunities, it can be really valuable to project yourself as a thought leader in the medical engagement space on social media.
#2 Possible collaborations with KOLs
Being passionate about a certain topic by being an active thought leader on social media can create opportunities for possible collaborations with KOLs, with KOLs reaching out to the MSLs themselves. An example of this when Luca mentioned is that if an MSL is very active on social media regarding real-world evidence and they constantly produce content on RWE, it's likely that some key opinion leaders and investigators may reach out for a proposal regarding collaboration on RWE because they observe that this MSL is knowledgeable about this topic.
#3 Medical education and leveraging social media machine learning
MSLs and medical affairs can run medical education programs on social media and Twitter in particular. They can also benefit from such content on social media to learn more about their work, and the community.
Medical affairs can address medical education needs more if they leverage the machine-learning algorithm of social media to serve content that is relevant for the stakeholder, in this case, physicians who have educational needs. Luca cited an example of video streaming sites like YouTube or TikTok that currently adapt to the needs of the viewers by having their algorithms learn what they are watching and skipping on the platform. This kind of automation and machine learning is constantly learning what works and what doesn't, a similar principle can be applied to medical affairs.
#1 Compliance as a major hurdle to move beyond social listening
It is one of the major factors why medical affairs professionals and MSLs are less oriented toward engagement in social media. Medical affairs professionals are not supposed to speak on behalf of the organization unless they have permission to do so. Partnering with legal and compliance colleagues is of tremendous importance since rules and regulations vary across different regions. It is very important to make it clear that the views expressed on social media are personal and do not represent the organization.
In the current landscape, the MSLs and medical affairs are still trying to figure out the right etiquette and the right rules to engage on social channels in a compliant way. Bruno exclaimed, “Sometimes compliance is a bit of an excuse to engage less on social, but it is changing slowly”.
The panelists discussed the value of being authentic on social media and hence progressing from just social listening to actively participating. There could be two approaches to this.
One, compartmentalizing your behavior and content as per the channel it is being posted on, however in no way being unauthentic. Bruno mentioned that the current standards of professionalism are evolving towards unifying the different components of who we are.
Two, projecting yourself as the person you are on all social channels and still staying within the framework of compliance.
#3 Newer tools like ClubHouse
Social media for MSLs and medical affairs is moving beyond passive listening to being active communities. Clubhouse is one of the newer tools with new clubs for pharma in general and medical affairs professionals, in particular, emerging since its launch.
Listen to the podcast below.
79% had reduction in disease. ORR 31%. Many responses deepen over time.
Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.
Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated
Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A
@montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!
CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe
Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt
Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7
@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm
Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy
Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network